Perrigo Company Trials - LARVOL Sigma

39 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company

2017-005120-16: Ulipristal versus surgery for symptomatic uterine fibroids Ulipristal (een medicijn) versus operatieve behandeling bij symptomatische vleesbomen in de baarmoeder.

Not yet recruiting

179

Europe

Esmya, Tablet, Esmya

Amsterdam UMC, Location VUmc, ZonMW

Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard, preferably laparoscpically, because it removes the fibroids entirely. Ulipristal, a selective progesterone receptor modulator, was introduced in 2012 as a new revolutionary (long-term) treatment for symptomatic uterine fibroids. It claims to make invasive treatment unnecessary. Myomen van de uterus komen veel voor. (Laparoscopische) myomectomie is de gouden standaard, gezien het feit dat de myomen in geheel wordt verwijderd. Ulipristal, een selectieve progesteron receptor modulator, is in 2012 op de markt gekomen als een nieuwe, revolutionaire (lange termijn) behandeling voor symptomatische uterine myomen. Het claimt invasieve behandeling te kunnen voorkomen., Uterine fibroids are very common. Sometimes surgical removal is necessary. However, ulipristal, a new medicine for treatment of symptomatic fibroids, claims to make invasive treatment unnecessary. Myomen (vleesbomen) van de baarmoeder komen veel voor. Soms is chirugische verwijdering noodzakelijk. Ulipristal is een nieuw medicijn dat beweert chirurgische behandeling te kunnen voorkomen., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

NCT05674513: Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

Recruiting

140

Ulipristal acetate

Oregon Health and Science University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Contraceptive Usage

12/26

12/27

2014-003408-65: Comparison of drug ulipristal acetate with existing treatment of levonorgestrel-releasing intra-uterine system.

Ongoing

220

Europe

Ulipristal acetate, Levonorgestrel-releasing intra-uterine system, Tablet, , Esmya, Mirena

University of Edinburgh, NHS Lothian

Heavy menstrual bleeding, Heavy menstrual bleeding, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

NCT06727734: Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

Not yet recruiting

980

Levonorgestrel, Anlitin, Piroxicam, CP-Pirox, Ulipristal Acetate, Ella, Placebo - LNG, Placebo - Piroxicam, Placebo - UPA

The University of Hong Kong, The Family Planning Association of Hong Kong

Contraception

09/27

10/27

2013-005494-53: A Study of the Histological Changes within Ectopic Endometrial Tissue, in Subjects with Pelvic Endometriosis- Following Treatment with Ulipristal Acetate, a Selective Progesterone Receptor Modulator (SPRM).

Ongoing

Europe

Ulipristal Acetate (Esmya), Tablet, Esmya

Norfolk and Norwich University Hospitals NHS Foundation Trust, PregLem SA

Endometriosis, Endometriosis, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

2016-001719-19: Can a selective progesterone receptor modulator be used for treatment of premenstrual dysphoric disorder? Kan en selektiv progesteronreceptor-modulerare användas för behandling av premenstruell dysfori?

Ongoing

100

Europe

esmya, Tablet, Esmya

Uppsala University, Uppsala University

Premenstrual dysphoric disorder Premenstruell dysfori, Premenstrual dysphoric disorder Premenstruell dysfori, Psychiatry and Psychology [F] - Mental Disorders [F03]

BC-APPS1, NCT02408770 / 2015-001587-19: Breast Cancer - Anti-Progestin Prevention Study 1

Completed

Europe

ulipristal acetate, Esmya

Manchester University NHS Foundation Trust, University of Manchester

Breast Cancer

03/19

01/23

NCT05216952: Ulipristal Acetate for Use in Early Pregnancy Loss

Completed

Ulipristal Acetate Tablets, Ella, Misoprostol Pill, Cytotec

University of North Carolina, Chapel Hill, North Carolina Translational and Clinical Sciences Institute

Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy

01/23

04/23

NCT04291001: Ovarian Function With ENG Implant and UPA Use

Completed

ENG implant, Nexplanon, oral ulipristal acetate, Ella

University of Utah, Merck Sharp & Dohme LLC

Contraception

10/22

01/24

Premium, NCT02748460: Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

Active, not recruiting

N/A

1500

Europe, RoW

PregLem SA

Uterine Fibroids

12/22

NCT05285605: Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

Completed

N/A

Ulipristal Acetate, Ella

Northwestern University, Society of Family Planning

Contraception, Contraceptive Usage, Reproductive Issues

03/23

01/24

NCT04028986: Esmya Versus Surgery Before IVF/ICSI

Active, not recruiting

N/A

Europe

Ulipristal Acetate 5 MG Oral Tablet, surgery for fibroid

Universitair Ziekenhuis Brussel

Fibroid; Uterus Tumor, Complicating Pregnancy, Infertility, Female, Surgical Procedure, Unspecified

12/25

06/26

Lysodren (mitotane) / Perrigo Company

ACTRN12613000058774: Mitotane Therapeutic Drug Monitoring Study: Assessing Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults

Recruiting

Calvary Mater Newcastle , Hunter Medical Research Institute

Adrenocortical cancer

ARAR0332, NCT00304070: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed

Canada, US, RoW

Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Conventional Surgery, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim-aafi, Filgrastim-ayow, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tevagrastim, Mitotane, (o,p)-DDD, 1, 1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane, 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene, 2, 2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane, 2, 4'-Dichlorodiphenyldichloroethane, CB 313, CB-313, Chloditan, Chlodithane, DDD, Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-, Khloditan, Lisodren, Lysodren, Mytotan, o,p' - DDD, o,p'-DDD, Ortho,para-DDD, WR-13045, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo

Children's Oncology Group, National Cancer Institute (NCI)

Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7

12/15

06/23

2018-000580-90: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Studio multicentrico, randomizzato, in aperto di fase III volto a valutare l’attività di chemioterapia adiuvante versus osservazione/mitotane dopo chirurgia di prima linea in pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva (ACACIA)

Ongoing

200

Europe

CISPLATINO, etoposide, mitotano, [CISPLATINO], [etoposide], [mitotano], Solution for infusion, Solution for injection, Tablet, CISPLATINO ACCORD HEALTHCARE ITALIA - 1MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML, ETOPOSIDE TEVA - 1 FLACONE 10 ML 20MG/ML, LYSODREN - 500 MG-COMPRESSE-USO ORALE-FLACONE(HDPE) 100 COMPRESSE

AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, AIFA - Italian Medicines Agency

localized Adrenocortical CarcInomA with high risk of recurrence pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva, Adrenocortical CarcInomA carcinoma corticosurrenale, Diseases [C] - Cancer [C04]

ADIUVO-2, NCT03583710: Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Recruiting

240

Europe, US

M.D. Anderson Cancer Center, National Cancer Institute (NCI), Assistance Publique - Hôpitaux de Paris, University Hospital Wurzburg, University Hospital Munich, Skanes Universitetssjukhus

ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma

01/29

2005-004354-27: STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME

Ongoing

Europe

NA, NA,

AZIENDA OSPEDALIERA S. LUIGI GONZAGA

Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer

2020-004530-38: PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENAL CORTICAL (PESETA TRIAL) Studio prospettico, di fase II volto a valutare l’efficacia dell’aggiunta di progesterone alla chemioterapia standard secondo schema EDP + mitotane nei pazienti affetti da carcinoma della corticale del surrene avanzato.

Not yet recruiting

Europe

megace, [megace], Tablet, MEGACE - 160 MG COMPRESSE 30 COMPRESSE

AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, UNIVERSITA' DEGLI STUDI DI BRESCIA_ BANDO AIRC

advanced/ metastatic patients with ACC carcinoma della corticale del surrene avanzato, advanced/ metastatic patients with ACC carcinoma della corticale del surrene avanzato, Diseases [C] - Cancer [C04]

NCT06831175: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting

RoW

Camrelizumab, Apatinib, Rivoceranib, YN968D1, mitotane

West China Hospital

Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer

12/26

12/31

ACCOMPLISH, NCT05036434: Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Enrolling by invitation

RoW

Pembrolizumab / Lenvatinib

National Cancer Center, Korea, MSD Korea Ltd.

Adrenocortical Carcinoma

08/25

08/26

NCT05634577: A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Terminated

Mitotane, Pembrolizumab

M.D. Anderson Cancer Center

Adrenocortical Carcinoma

07/24

ChiCTR2500099472: The Efficacy and Safety of Toripalimab in Advanced Adrenal Cortical Carcinoma, an Investigator-initiated, Prospective, Randomized Controlled, Phase II Clinical Trial

Not yet recruiting

Mitotane; Toripalimab combined with Mitotane

Peking Union Medical College Hospital; Peking Union Medical College Hospital, CAMS Innovation Fund for Medical Sciences（CIFMS）

Advanced Adrenal Cortical Carcinoma

PESETA, NCT05913427 / 2020-004530-38: Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Recruiting

Europe

Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Megace, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo, placebo

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, UNIVERSITA' DEGLI STUDI DI BRESCIA_ BANDO AIRC

Adrenocortical Carcinoma

06/27

MitoS-FP, NCT05344027: The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

Completed

N/A

Europe

Mitotane

King's College Hospital NHS Trust

Adrenocortical Carcinoma

01/23

03/23

NCT00568139: Evaluation of Side Effects of Mitotane

Active, not recruiting

N/A

400

Europe

University of Wuerzburg

Adrenocortical Carcinoma

12/24

12/25

MAE, NCT05839886: The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma

Not yet recruiting

N/A

Shanghai Jiao Tong University School of Medicine

Adrenocortical Carcinoma

05/24

12/24

ChiCTR2300073328: Clinical study protocol of blood concentration monitoring and population analysis of mitotane in Chinese

Not yet recruiting

N/A

West China Hospital of Sichuan University; West China Hospital of Sichuan University, Funded by West China Hospital of Sichuan University, Project ID: 2023HXFH027.

adrenocortical carcinoma

Metopirone (metyrapone) / Perrigo Company

2007-000137-19: Metyrapone as additive treatment in patients with major depression

Ongoing

Europe

Metopiron, Metopiron

Leiden University Medical Center

unipolar depressive episode without psychotic features according to DSM-IV-TR

2019-002008-41: Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome Effetto della terapia con Metirapone sul rischio cardiovascolare in pazienti con incidentalomi surrenalici e sindrome di Cushing subclinica

Ongoing

Europe

CORMETO, [CORMETO], Capsule, soft, CORMETO - "250 MG CAPSULE MOLLI" 50 CAPSULE IN FLACONE HDPE

AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, AIFA - Italian Medicines Agency

patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome incidentalomi surrenalici e sindrome di Cushing subclinica, patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome incidentalomi surrenalici e sindrome di Cushing subclinica, Diseases [C] - Hormonal diseases [C19]

NCT06801249: Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

Recruiting

Europe

Metarapone, Standardized antihypertensive therapy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Adrenal Incidentalomas, Cushing Syndrome

11/24

02/25

2022-000161-40: Investigating the effects of mildly increased cortisol secretion on cardio metabolic risk factors

Ongoing

Europe

Metopirone, Capsule, Metopirone

Medical University of Vienna, Division of Endocrinology, Medical University of Vienna

Autonomous cortisol secretion in patients with adrenal adenoma, Autonomous cortisol secretion, Diseases [C] - Hormonal diseases [C19]

2022-002241-18: Diagnostic treatment-trial for autonomous cortisol secretion- a tool to select patients for adrenalectomy

Not yet recruiting

100

Europe

Capsule, soft, Metycor

Helse Bergen HF, Helse Bergen HF

autonomous cortisol secretion, autonomous cortisol secretion, Diseases [C] - Hormonal diseases [C19]

2013-002063-26: A trial with Metyrapone in Cushing's syndrome Trial clinico con Metopirone nella sindrome di Cushing

Ongoing

Europe

Metyrapone, Metyrapone, Capsule, soft, Matyrapone

S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano, HRA Pharma

Cushing's syndrome Malattia di Cushing, Cushing's disease Malattia di Cushing, Diseases [C] - Hormonal diseases [C19]

SEP-1, NCT06768944: Stress Experience Following Psilocybin

Not yet recruiting

Canada

Psilocybin 25 mg, PEX010, high-dose psilocybin, Psilocybin 1 mg, low-dose psilocybin, Metyrapone 750 mg, Metopirone, Placebo

University of Calgary

Assessing the Importance of Cortisol in Facilitating Positive Outcomes Induced by Psilocybin in Healthy Participants

09/27

10/27

MACS, NCT06106295: Metyrapone for Mild Autonomous Cortisol Secretion

Recruiting

Metyrapone

Mayo Clinic

Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)

01/28

Gluco-Feed, NCT05167084: Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals

Completed

Europe

Metyrapone 250 mg Oral Tablets, Placebo 250 mg Tablets, Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo (0,9% NaCl solution)

Eleonora Seelig

Glucocorticoid Effect

06/23

NCT05919992: The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)

Completed

Europe

Metyrapone 250 mg Oral Tablets, Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo 250 mg Tablets, Placebo (0,9% NaCl solution)

Eleonora Seelig

Glucocorticoid Effect

07/24

CEM, NCT05255900: Effects of Metyrapone in Patients With Hypercortisolism

Recruiting

N/A

Europe

Metyrapone Capsules

Istituto Auxologico Italiano, HRA Pharma

Hypercortisolism

12/24

Gluco-Max, NCT06556277: Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake

Recruiting

N/A

Europe

Metyrapone And Hydrocortisone, Placebo

Eleonora Seelig

Glucocorticoids, Overweight and Obesity, Overeating

07/26

ELN 582175 / Perrigo Company

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company

2017-005120-16: Ulipristal versus surgery for symptomatic uterine fibroids Ulipristal (een medicijn) versus operatieve behandeling bij symptomatische vleesbomen in de baarmoeder.

Not yet recruiting

179

Europe

Esmya, Tablet, Esmya

Amsterdam UMC, Location VUmc, ZonMW

NCT05674513: Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

Recruiting

140

Ulipristal acetate

Oregon Health and Science University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Contraceptive Usage

12/26

12/27

2014-003408-65: Comparison of drug ulipristal acetate with existing treatment of levonorgestrel-releasing intra-uterine system.

Ongoing

220

Europe

Ulipristal acetate, Levonorgestrel-releasing intra-uterine system, Tablet, , Esmya, Mirena

University of Edinburgh, NHS Lothian

Heavy menstrual bleeding, Heavy menstrual bleeding, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

NCT06727734: Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

Not yet recruiting

980

Levonorgestrel, Anlitin, Piroxicam, CP-Pirox, Ulipristal Acetate, Ella, Placebo - LNG, Placebo - Piroxicam, Placebo - UPA

The University of Hong Kong, The Family Planning Association of Hong Kong

Contraception

09/27

10/27

Ongoing

Europe

Ulipristal Acetate (Esmya), Tablet, Esmya

Norfolk and Norwich University Hospitals NHS Foundation Trust, PregLem SA

Endometriosis, Endometriosis, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Ongoing

100

Europe

esmya, Tablet, Esmya

Uppsala University, Uppsala University

Premenstrual dysphoric disorder Premenstruell dysfori, Premenstrual dysphoric disorder Premenstruell dysfori, Psychiatry and Psychology [F] - Mental Disorders [F03]

BC-APPS1, NCT02408770 / 2015-001587-19: Breast Cancer - Anti-Progestin Prevention Study 1

Completed

Europe

ulipristal acetate, Esmya

Manchester University NHS Foundation Trust, University of Manchester

Breast Cancer

03/19

01/23

NCT05216952: Ulipristal Acetate for Use in Early Pregnancy Loss

Completed

Ulipristal Acetate Tablets, Ella, Misoprostol Pill, Cytotec

University of North Carolina, Chapel Hill, North Carolina Translational and Clinical Sciences Institute

Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy

01/23

04/23

NCT04291001: Ovarian Function With ENG Implant and UPA Use

Completed

ENG implant, Nexplanon, oral ulipristal acetate, Ella

University of Utah, Merck Sharp & Dohme LLC

Contraception

10/22

01/24

Premium, NCT02748460: Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

Active, not recruiting

N/A

1500

Europe, RoW

PregLem SA

Uterine Fibroids

12/22

NCT05285605: Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

Completed

N/A

Ulipristal Acetate, Ella

Northwestern University, Society of Family Planning

Contraception, Contraceptive Usage, Reproductive Issues

03/23

01/24

NCT04028986: Esmya Versus Surgery Before IVF/ICSI

Active, not recruiting

N/A

Europe

Ulipristal Acetate 5 MG Oral Tablet, surgery for fibroid

Universitair Ziekenhuis Brussel

Fibroid; Uterus Tumor, Complicating Pregnancy, Infertility, Female, Surgical Procedure, Unspecified

12/25

06/26

Lysodren (mitotane) / Perrigo Company

ACTRN12613000058774: Mitotane Therapeutic Drug Monitoring Study: Assessing Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults

Recruiting

Calvary Mater Newcastle , Hunter Medical Research Institute

Adrenocortical cancer

ARAR0332, NCT00304070: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed

Canada, US, RoW

Children's Oncology Group, National Cancer Institute (NCI)

Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7

12/15

06/23

Ongoing

200

Europe

AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, AIFA - Italian Medicines Agency

ADIUVO-2, NCT03583710: Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Recruiting

240

Europe, US

M.D. Anderson Cancer Center, National Cancer Institute (NCI), Assistance Publique - Hôpitaux de Paris, University Hospital Wurzburg, University Hospital Munich, Skanes Universitetssjukhus

ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma

01/29

2005-004354-27: STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME

Ongoing

Europe

NA, NA,

AZIENDA OSPEDALIERA S. LUIGI GONZAGA

Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer

Not yet recruiting

Europe

megace, [megace], Tablet, MEGACE - 160 MG COMPRESSE 30 COMPRESSE

AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, UNIVERSITA' DEGLI STUDI DI BRESCIA_ BANDO AIRC

NCT06831175: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting

RoW

Camrelizumab, Apatinib, Rivoceranib, YN968D1, mitotane

West China Hospital

Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer

12/26

12/31

ACCOMPLISH, NCT05036434: Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Enrolling by invitation

RoW

Pembrolizumab / Lenvatinib

National Cancer Center, Korea, MSD Korea Ltd.

Adrenocortical Carcinoma

08/25

08/26

NCT05634577: A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Terminated

Mitotane, Pembrolizumab

M.D. Anderson Cancer Center

Adrenocortical Carcinoma

07/24

ChiCTR2500099472: The Efficacy and Safety of Toripalimab in Advanced Adrenal Cortical Carcinoma, an Investigator-initiated, Prospective, Randomized Controlled, Phase II Clinical Trial

Not yet recruiting

Mitotane; Toripalimab combined with Mitotane

Peking Union Medical College Hospital; Peking Union Medical College Hospital, CAMS Innovation Fund for Medical Sciences（CIFMS）

Advanced Adrenal Cortical Carcinoma

PESETA, NCT05913427 / 2020-004530-38: Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Recruiting

Europe

Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Megace, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo, placebo

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, UNIVERSITA' DEGLI STUDI DI BRESCIA_ BANDO AIRC

Adrenocortical Carcinoma

06/27

MitoS-FP, NCT05344027: The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

Completed

N/A

Europe

Mitotane

King's College Hospital NHS Trust

Adrenocortical Carcinoma

01/23

03/23

NCT00568139: Evaluation of Side Effects of Mitotane

Active, not recruiting

N/A

400

Europe

University of Wuerzburg

Adrenocortical Carcinoma

12/24

12/25

MAE, NCT05839886: The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma

Not yet recruiting

N/A

Shanghai Jiao Tong University School of Medicine

Adrenocortical Carcinoma

05/24

12/24

ChiCTR2300073328: Clinical study protocol of blood concentration monitoring and population analysis of mitotane in Chinese

Not yet recruiting

N/A

West China Hospital of Sichuan University; West China Hospital of Sichuan University, Funded by West China Hospital of Sichuan University, Project ID: 2023HXFH027.

adrenocortical carcinoma

Metopirone (metyrapone) / Perrigo Company

2007-000137-19: Metyrapone as additive treatment in patients with major depression

Ongoing

Europe

Metopiron, Metopiron

Leiden University Medical Center

unipolar depressive episode without psychotic features according to DSM-IV-TR

Ongoing

Europe

CORMETO, [CORMETO], Capsule, soft, CORMETO - "250 MG CAPSULE MOLLI" 50 CAPSULE IN FLACONE HDPE

AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, AIFA - Italian Medicines Agency

NCT06801249: Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

Recruiting

Europe

Metarapone, Standardized antihypertensive therapy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Adrenal Incidentalomas, Cushing Syndrome

11/24

02/25

2022-000161-40: Investigating the effects of mildly increased cortisol secretion on cardio metabolic risk factors

Ongoing

Europe

Metopirone, Capsule, Metopirone

Medical University of Vienna, Division of Endocrinology, Medical University of Vienna

Autonomous cortisol secretion in patients with adrenal adenoma, Autonomous cortisol secretion, Diseases [C] - Hormonal diseases [C19]

2022-002241-18: Diagnostic treatment-trial for autonomous cortisol secretion- a tool to select patients for adrenalectomy

Not yet recruiting

100

Europe

Capsule, soft, Metycor

Helse Bergen HF, Helse Bergen HF

autonomous cortisol secretion, autonomous cortisol secretion, Diseases [C] - Hormonal diseases [C19]

2013-002063-26: A trial with Metyrapone in Cushing's syndrome Trial clinico con Metopirone nella sindrome di Cushing

Ongoing

Europe

Metyrapone, Metyrapone, Capsule, soft, Matyrapone

S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano, HRA Pharma

Cushing's syndrome Malattia di Cushing, Cushing's disease Malattia di Cushing, Diseases [C] - Hormonal diseases [C19]

SEP-1, NCT06768944: Stress Experience Following Psilocybin

Not yet recruiting

Canada

Psilocybin 25 mg, PEX010, high-dose psilocybin, Psilocybin 1 mg, low-dose psilocybin, Metyrapone 750 mg, Metopirone, Placebo

University of Calgary

Assessing the Importance of Cortisol in Facilitating Positive Outcomes Induced by Psilocybin in Healthy Participants

09/27

10/27

MACS, NCT06106295: Metyrapone for Mild Autonomous Cortisol Secretion

Recruiting

Metyrapone

Mayo Clinic

Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)

01/28

Gluco-Feed, NCT05167084: Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals

Completed

Europe

Metyrapone 250 mg Oral Tablets, Placebo 250 mg Tablets, Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo (0,9% NaCl solution)

Eleonora Seelig

Glucocorticoid Effect

06/23

NCT05919992: The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)

Completed

Europe

Metyrapone 250 mg Oral Tablets, Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo 250 mg Tablets, Placebo (0,9% NaCl solution)

Eleonora Seelig

Glucocorticoid Effect

07/24

CEM, NCT05255900: Effects of Metyrapone in Patients With Hypercortisolism

Recruiting

N/A

Europe

Metyrapone Capsules

Istituto Auxologico Italiano, HRA Pharma

Hypercortisolism

12/24

Gluco-Max, NCT06556277: Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake

Recruiting

N/A

Europe

Metyrapone And Hydrocortisone, Placebo

Eleonora Seelig

Glucocorticoids, Overweight and Obesity, Overeating

07/26

ELN 582175 / Perrigo Company

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites